WASHINGTON — Tissue engineering in its various forms might prove clinically useful more rapidly than the genomics and proteomics that drive so much research, but the manipulation of cells is known to carry with it a more or less unique set of hazards. A member of the FDA team appeared at this year's annual meeting of the Tissue Engineering and Regenerative Medicine International Society (TERMIS; San Ramon, California) and advised attendees that he is on board with the view that the lack of standards and a lack of product consistency combine to form "possibly the greatest challenge" facing such products on the road to clinical use.